“Delivery” remains the foundation of success, praying that PYC has pioneered a platform that will help us leapfrog into success:
quote from the article that I found relevant to PYC current state:
“…Without a doubt, conquering delivery was foundational to building Alnylam. It was the key technology hurdle to turning Nobel-prize-winning science into medicine.
There was never a ‘straight line’ to a solution—there rarely is in either science or business.
Ultimately, the key was to persevere, follow the science and foster an environment of innovation. The ultimate solutions relied on fundamental advances in both novel delivery methods andnovel chemistry applied to the siRNA itself.
It was also critical to be bold and take risks, bringing prototypes into early clinical studies and learning (safely, of course) how to optimize based on findings in man.
Finally, Delivery (capital ‘D’) has never been ‘over’ for us. We have continued (and continue) to optimize the technology to bring our best innovations to patients...”
PYC Price at posting:
8.8¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)